293 related articles for article (PubMed ID: 28606339)
21. The EMPA-REG study: What has it told us? A diabetologist's perspective.
DeFronzo RA
J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076
[No Abstract] [Full Text] [Related]
22. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
Mazer CD; Hare GMT; Connelly PW; Gilbert RE; Shehata N; Quan A; Teoh H; Leiter LA; Zinman B; Jüni P; Zuo F; Mistry N; Thorpe KE; Goldenberg RM; Yan AT; Connelly KA; Verma S
Circulation; 2020 Feb; 141(8):704-707. PubMed ID: 31707794
[No Abstract] [Full Text] [Related]
23. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
Thompson J; Schacht S; Rothenberg F
Cardiol Clin; 2019 Aug; 37(3):335-343. PubMed ID: 31279427
[TBL] [Abstract][Full Text] [Related]
24. Sodium glucose co-transporter 2 inhibitors in heart failure therapy.
Çavuşoğlu Y; Altay H; Cahn A; Celik A; Demir S; Kılıçaslan B; Nalbantgil S; Raz I; Temizhan A; Yıldırımtürk Ö; Yılmaz MB
Turk Kardiyol Dern Ars; 2020 Apr; 48(3):330-354. PubMed ID: 32281958
[No Abstract] [Full Text] [Related]
25. Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.
Suissa S
Circulation; 2018 Apr; 137(14):1432-1434. PubMed ID: 29610125
[No Abstract] [Full Text] [Related]
26. Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
Aschenbrenner DS
Am J Nurs; 2021 Sep; 121(9):25. PubMed ID: 34438427
[TBL] [Abstract][Full Text] [Related]
27. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
28. Promise, Innovation, Potency, and Efficacy: The PIPE Dream of Sodium-Glucose Co-Transporter 2 Inhibitors.
Butler J
Am J Cardiol; 2019 Dec; 124 Suppl 1():S1-S2. PubMed ID: 31741434
[No Abstract] [Full Text] [Related]
29. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
[TBL] [Abstract][Full Text] [Related]
30. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
Kappel BA; Lehrke M; Schütt K; Artati A; Adamski J; Lebherz C; Marx N
Circulation; 2017 Sep; 136(10):969-972. PubMed ID: 28874423
[No Abstract] [Full Text] [Related]
31. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
Claggett B; Lachin JM; Hantel S; Fitchett D; Inzucchi SE; Woerle HJ; George JT; Zinman B
Circulation; 2018 Oct; 138(15):1599-1601. PubMed ID: 30354516
[No Abstract] [Full Text] [Related]
32. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
33. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
Ingelfinger JR; Rosen CJ
N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
[No Abstract] [Full Text] [Related]
34. Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
Slomski A
JAMA; 2022 Sep; 328(9):817. PubMed ID: 36066528
[No Abstract] [Full Text] [Related]
35. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
Katsiki N; Triposkiadis F
Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
[No Abstract] [Full Text] [Related]
36. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
[TBL] [Abstract][Full Text] [Related]
37. Empagliflozin (Jardiance) for heart failure.
Med Lett Drugs Ther; 2020 Nov; 62(1611):177-178. PubMed ID: 33438858
[No Abstract] [Full Text] [Related]
38. Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.
Verma S; McGuire DK; Kosiborod MN
Circulation; 2020 Dec; 142(23):2201-2204. PubMed ID: 32969716
[No Abstract] [Full Text] [Related]
39. Slowing Progression in CKD: DAPA CKD and Beyond.
Larmour K; Levin A
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
[No Abstract] [Full Text] [Related]
40. [Diabetes mellitus. SGLT2 inhibitor reduces cardiovascular mortality].
Overbeck P
MMW Fortschr Med; 2015 Oct; 157(17):16. PubMed ID: 26759859
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
